3
Announcements
Trials
Browse
Landscape
Status
Enrolling by invitation
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Neoplasms
12
Breast Neoplasms
11
Prostatic Neoplasms
5
Lung Neoplasms
5
Colorectal Neoplasms
5
Uterine Cervical Neoplasms
4
Thyroid Neoplasms
2
Smoking Cessation
2
Motor Activity
2
Lymphoma
2
Hematologic Neoplasms
2
Communication
2
Uveal Melanoma
1
Uterine Cervical Dysplasia
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Tobacco Use Cessation
1
Thyroid Diseases
1
Squamous Cell Carcinoma of Head and Neck
1
Smoking
1
Sexual Dysfunction, Physiological
1
Sedentary Behavior
1
Rectal Neoplasms
1
Patient Preference
1
Patient Acceptance of Health Care
1
Papillomavirus Infections
1
Papillary Thyroid Microcarcinoma
1
Neoplasms, Plasma Cell
1
Multiple Myeloma
1
Melanoma
1
Interventions
pembrolizumab
37
Gemcitabine
29
Nivolumab
20
Cisplatin
19
atezolizumab
15
avelumab
14
Docetaxel
13
enfortumab vedotin
10
Carboplatin
10
durvalumab
9
Magnetic Resonance Spectroscopy
9
Ipilimumab
8
Paclitaxel
7
Pemetrexed
6
toripalimab
5
cabozantinib
5
Fluorodeoxyglucose F18
5
sacituzumab govitecan
4
cabazitaxel
4
Taxes
4
vinflunine
3
tremelimumab
3
pemigatinib
3
X-Rays
3
Standard of Care
3
Specimen Handling
3
Radiotherapy
3
Mitomycin
3
Immunotherapy
3
Immunoglobulin G
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Carcinoma, Transitional Cell
×
Focus Groups
×
Clear all
NCT07091565
2025-08-03
SPARC
King's College London
Enrolling by invitation
60 enrolled